Compare VanEck Uranium & Nuclear ETF (NLR) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Uranium & Nuclear ETF vs Organon & Co. Common Stock — how do they compare? VanEck Uranium & Nuclear ETF trades at $92.57 (market cap $3.37B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: VanEck Uranium & Nuclear ETF and Organon & Co. Common Stock are close in size by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while VanEck Uranium & Nuclear ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Uranium & Nuclear ETF for 9 Days and Organon & Co. Common Stock for 0 Days on average.
| NLR | OGN | |
|---|---|---|
Market Cap | $3.37B | $3.62B |
Volume | 376,734 | 2,892,999 |
Sector | Sector/Thematic | Health |
52-Week High | $164.37 | $13.81 |
52-Week Low | $94.52 | $5.70 |
Typical Hold Time | 9 Days | 0 Days |
Enterprise Value | — | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NLR, the VanEck Uranium and Nuclear ETF, trades at $99.38, down 0.82% on the day amid a bearish technical signal. The ETF is positioned to benefit from growing demand for nuclear power driven by AI data centers and government support, as highlighted by recent news of a major Google-Constellation deal and U.S. funding for new reactors. However, key financial ratios are unavailable, and technical indicators show selling pressure with moving averages and oscillators in bearish alignment.
The outlook for NLR is mixed, with long-term catalysts from nuclear energy adoption offset by near-term volatility and lack of transparent fundamentals. Risks include sector-specific headwinds and expense ratio comparisons, but institutional interest from firms like Bank of America suggests confidence. Investors should weigh the ETF's thematic exposure against its technical weakness and opaque financial metrics.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About VanEck Uranium & Nuclear ETF
VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.
Read more on NLR →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
